Demonstration Formulary
6 Endocrine system
06-04-01-02 Progestogens
| Medroxyprogesterone Acetate Sayana press® |
|
Formulary
|
Suitable for self injection in patients who have had appropriate tranining |
|
| Ulipristal acetate Esmya® |
|
Non Formulary
|
MHRA March 2020 Esmya (ulipristal acetate): suspension of the licence due to risk of serious liver injury July 2018 - Traffic light status amended to RED in light of EMA update Esmya: new measures to minimise risk of rare but serious liver injury The only indication approved for use by the APC is |
 EMA June 2018: Esmya: new measures to minimise risk of rare but serious liver injury MHRA February 2018: Esmya (ulipristal acetate) for uterine fibroids: do not initiate or re-start treatment; monitor liver function in current and recent users |
|
Links
- DVLA guidance
- EMA June 2018: Esmya: new measures to minimise risk of rare but serious liver injury
- MHRA February 2018: Esmya (ulipristal acetate) for uterine fibroids: do not initiate or re-start treatment; monitor liver function in current and recent users
- NICE Guidance on prescribing
- NICE NG28: Type 2 diabetes in adults: management
- NICE NG88: Heavy menstrual bleeding: assessment and management